Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Meghna MehtaJames GriffithJanani PanneerselvamAnish BabuJonathan ManiTerence HermanRajagopal RameshAnupama MunshiPublished in: International journal of radiation biology (2020)
Our findings demonstrate that Regorafenib enhanced radiosensitivity of breast cancer cells by inhibiting the expression of multiple receptor tyrosine kinases, VEGF-mediated angiogenesis and DNA damage response in TNBC. Therefore, combining Regorafenib with radiation and antiangiogenic agents will be beneficial and effective in controlling TNBC.
Keyphrases
- breast cancer cells
- endothelial cells
- dna damage response
- metastatic colorectal cancer
- dna damage
- dna repair
- vascular endothelial growth factor
- signaling pathway
- poor prognosis
- oxidative stress
- binding protein
- induced apoptosis
- radiation induced
- induced pluripotent stem cells
- pluripotent stem cells
- long non coding rna
- radiation therapy